Dr. Ronnie Shapira-Frommer
MD, Oncology
Director, Ella Lemelbaum Institute for Immuno-Oncology and Melanoma
corporate_fareSheba Medical Center, Tel Hashomer, Israel
Ronnie Shapira-Frommer
MD, Oncology
Dr. Ronnie Shapira-Frommer is a senior medical oncologist at Sheba Medical Center, Israel, and Director of the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma. Her clinical work centres on advanced melanoma, immune checkpoint inhibitor therapy, tumour-infiltrating lymphocyte therapy, and gynaecologic cancers.
Dr. Shapira-Frommer completed her medical degree at the Faculty of Medicine, Tel Aviv University, followed by internal medicine specialisation at Meir Medical Center and oncology specialisation at Sheba Medical Center. She served as Senior Oncologist at Sheba from 2009 to 2015 and as Director of the Onco-Gynaecology Service from 2015 to 2021, before assuming her current directorship role at the Ella Lemelbaum Institute in 2021. Her research spans immunotherapy resistance, adoptive cell therapy, and real-world outcomes in metastatic melanoma. She is a Principal Investigator on a ClinicalTrials.gov-registered Sheba study addressing primary resistance to immunotherapy in BRAF-mutated metastatic melanoma.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Dr. Shapira-Frommer at Sheba Medical Center.
Why Consider Dr. Ronnie Shapira-Frommer?
Dr. Shapira-Frommer leads one of Israel's foremost melanoma and immuno-oncology centres, combining deep clinical expertise in advanced melanoma with active involvement in clinical research and adoptive cell therapy programmes.
Areas of Specialisation
Advanced melanoma, immuno-oncology, and gynaecologic cancer care at Sheba Medical Center
Dr. Shapira-Frommer's clinical practice spans advanced melanoma, immune checkpoint-based treatment, adoptive cell therapy, and gynaecologic oncology. Her work integrates research-based protocols with individualised patient care.
Melanoma & Immuno-Oncology
Comprehensive management of advanced and metastatic melanoma using immunotherapy, targeted therapy, and cellular approaches.
- arrow_rightPD-1 inhibitor-based treatment planning (pembrolizumab, nivolumab) for advanced melanoma
- arrow_rightCTLA-4 and combination checkpoint blockade for eligible patients
- arrow_rightAssessment and management of immunotherapy resistance
- arrow_rightTIL-based adoptive cell therapy for refractory metastatic melanoma
- arrow_rightLymphodepleting preparative regimens prior to TIL infusion
- arrow_rightResearch-based protocols within the Ella Lemelbaum Institute programme
- arrow_rightBRAF V600E/K mutation-directed targeted therapy planning
- arrow_rightClinical trial access for BRAF-mutated melanoma with immunotherapy resistance
Gynaecologic Oncology
Multidisciplinary medical oncology care for ovarian, cervical, endometrial, and gynaecologic malignancies.
- arrow_rightSystemic treatment planning for ovarian, cervical, and endometrial cancers
- arrow_rightMultidisciplinary care coordination with surgical and radiation oncology teams
- arrow_rightVulvar and vaginal melanoma management within a combined specialty context
Procedures Performed
Clinical treatment approaches and oncology services
Dr. Shapira-Frommer's clinical work at the Ella Lemelbaum Institute covers immunotherapy protocols, cellular therapy, targeted systemic treatment, and multidisciplinary oncology care planning.
Immunotherapy Treatment
Medical OncologySystemic immunotherapy including checkpoint inhibitor protocols for advanced melanoma and eligible solid tumours.
Adoptive Cell Therapy
Complex DiseaseTIL-based adoptive cell therapy and related cellular immunotherapy approaches for refractory melanoma.
Targeted Therapy
Targeted TherapyMolecularly guided treatment for BRAF-mutated melanoma and other targetable malignancies.
Multidisciplinary Gynaecologic Cancer Care
MultidisciplinaryCoordinated treatment planning for gynaecologic malignancies in collaboration with surgical and radiation specialists.
Second Opinion Consultation
Second OpinionIndependent expert review for patients with melanoma or gynaecologic cancers seeking evaluation at Sheba Medical Center.
Research & Publications
Clinical research in melanoma immunotherapy, adoptive cell therapy, and gynaecologic oncology
Dr. Shapira-Frommer has contributed to peer-reviewed oncology research in melanoma immunotherapy, treatment discontinuation outcomes, TIL-based therapy, and gynaecologic oncology care.
Dr. Shapira-Frommer is an active Principal Investigator in melanoma immunotherapy research at Sheba Medical Center. CancerFax can assist with eligibility assessment for open studies.
Education & Training
Dr. Shapira-Frommer completed her medical training at Tel Aviv University and pursued specialisation in internal medicine and oncology at leading Israeli academic medical centres.
Clinical Experience
Dr. Shapira-Frommer has spent her entire clinical and academic career at Sheba Medical Center, progressing from oncology specialist training to her current directorship of the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma.
Languages & International
Dr. Shapira-Frommer conducts consultations in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients consulting at Sheba Medical Center.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Ronnie Shapira-Frommer
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Ronnie Shapira-Frommer's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Ronnie Shapira-Frommer's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Ronnie Shapira-Frommer before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Ronnie Shapira-Frommer's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Ronnie Shapira-Frommer's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Ronnie Shapira-Frommer's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Ronnie Shapira-Frommer
Dr. Ronnie Shapira-Frommer is a senior medical oncologist at Sheba Medical Center, Israel, and Director of the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma. She specialises in advanced melanoma, immunotherapy, tumour-infiltrating lymphocyte therapy, and gynaecologic cancers.
Dr. Shapira-Frommer specialises primarily in melanoma — including metastatic and immunotherapy-resistant melanoma — as well as other skin cancers and gynaecologic malignancies such as ovarian, cervical, and endometrial cancer. She also has experience with vulvar and vaginal melanoma within a combined melanoma and gynaecologic oncology context.
Yes. Her clinical and research focus includes advanced and metastatic melanoma, including patients with BRAF mutations and those who have developed resistance to standard immunotherapy. She leads a ClinicalTrials.gov-registered study at Sheba Medical Center specifically investigating strategies to overcome primary immunotherapy resistance in metastatic melanoma.
Dr. Shapira-Frommer is associated with immune checkpoint inhibitor therapy (PD-1 and CTLA-4 inhibitors), tumour-infiltrating lymphocyte (TIL) therapy, adoptive cell therapy, BRAF-directed targeted therapy, and clinical trial-based treatment for immunotherapy-resistant melanoma. She is also involved in systemic chemotherapy for gynaecologic cancers and multidisciplinary care planning.
Yes. Dr. Shapira-Frommer is listed as Principal Investigator on NCT05304546, a Sheba Medical Center study focused on overcoming primary resistance to immunotherapy in metastatic melanoma among patients with BRAF V600E/K mutations. CancerFax can assist with eligibility review for this and other open studies at Sheba.
Sheba Medical Center has a dedicated international patient pathway, and Dr. Shapira-Frommer's profile is available through Sheba's international website. CancerFax can coordinate medical-report review and consultation support for international patients, subject to hospital availability and case acceptance.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your case, prepare a structured summary, and coordinate the consultation with Dr. Shapira-Frommer at Sheba Medical Center, subject to availability. For second opinions, please include pathology reports, imaging, molecular profiling results, and your current treatment history.
Connect with Ronnie Shapira-Frommer Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.